[Reticulocyte response after immediate withdrawal of recombinant human erythropoietin in chronic hemodialysis patients].
Caramelo
C
C
Servicio de Hematología, Clínica de la Concepción, Universidad Autónoma de Madrid, Av. Reyes Católicos, 2 28040 Madrid. ccaramelo@fjd.es
Soto
C
C
Neira
F
F
López
M D
MD
Jiménez
S
S
Albalate
M
M
de Oña
R
R
Llamas
P
P
Deudero
J J P
JJ
D000368:Aged; D000740:Anemia / Q000188:drug therapy* / Q000209:etiology; D000818:Animals; D004300:Doping in Sports; D004334:Drug Administration Schedule; D000068817:Epoetin Alfa; D004920:Erythropoiesis / Q000187:drug effects; D004921:Erythropoietin / Q000008:administration & dosage* / Q000494:pharmacology / Q000627:therapeutic use; D005260:Female; D006400:Hematocrit; D006801:Humans; D007676:Kidney Failure, Chronic / Q000097:blood* / Q000150:complications / Q000628:therapy; D008297:Male; D008875:Middle Aged; D051381:Rats; D017208:Rats, Wistar; D011994:Recombinant Proteins; D012008:Recurrence; D006435:Renal Dialysis; D017701:Reticulocyte Count; D014511:Uremia / Q000097:blood / Q000150:complications / Q000628:therapy
D011994:Recombinant Proteins; D004921:Erythropoietin; D000068817:Epoetin Alfa
Respuesta reticulocitaria tras cese inmediato de administración de eritropoyetina recombinante humana en enfermos en hemodiálisis crónica. Implicaciones en la terapia de la anemia.